The research collaboration will leverage Mucosis' Mimopath platform technology in Crucell's program for developing undisclosed novel vaccines to combat infectious diseases.

Mucosis CEO Thomas Johnston said Mimopath platform combined with Crucell's expertise in vaccine development will create a substantial opportunity to develop differentiated and medically relevant vaccine candidates.

"We see this agreement as a further validation of our platform and its potential to combat infectious diseases," Johnston added.

According to the agreement, Mucosis will earn upfront payments and is eligible to receive additional payments on the achievement agreed upon milestones.

Financial details of the agreement were not revealed.